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InflammationAbstract The constitutively-expressed cyclooxygenase 1 (COX-1) and the inducible COX-2 are
both involved in the conversion of arachidonic acid (AA) to prostaglandins (PGs). However, the
functional roles of COX-1 at the cellular level remain unclear. We hypothesized that by comparing
differential gene expression and eicosanoid metabolism in lung fibroblasts from wild-type (WT) mice
and COX-2-/- or COX-1-/- mice may help address the functional roles of COX-1 in inflammation and
other cellular functions. Compared to WT, the number of specifically-induced transcripts
were altered descendingly as follows: COX-2-/- > COX-1-/- > WT+ IL-1b. COX-1-/- or
COX-2-/- cells shared about 50% of the induced transcripts with WT cells treated with IL-1b,
respectively. An interactive ‘‘anti-inflammatory, proinflammatory, and redox-activated” signature
in the protein–protein interactome map was observed in COX-2-/- cells. The augmented COX-1
mRNA (in COX-2-/- cells) was associated with the upregulation of mRNAs for glutathione
S-transferase (GST), superoxide dismutase (SOD), NAD(P)H dehydrogenase quinone 1 (NQO1),nces and
82 Genomics Proteomics Bioinformatics 14 (2016) 81–93aryl hydrocarbon receptor (AhR), peroxiredoxin, phospholipase, prostacyclin synthase, and pros-
taglandin E synthase, resulting in a significant increase in the levels of PGE2, PGD2, leukotriene
B4 (LTB4), PGF1a, thromboxane B2 (TXB2), and PGF2a. The COX-1 plays a dominant role in shift-
ing AA toward the LTB4 pathway and anti-inflammatory activities. Compared to WT, the upreg-
ulated COX-1 mRNA in COX-2-/- cells generated an ‘‘eicosanoid storm”. The genomic
characteristics of COX-2-/- is similar to that of proinflammatory cells as observed in IL-1b induced
WT cells. COX-1-/- and COX-2-/- cells exhibited compensation of various eicosanoids at the geno-
mic and metabolic levels.Introduction
Eicosanoids are lipid mediators of inflammation [1]. Cytosolic
phospholipase A2 (cPLA2) cleaves some membrane lipids to
generate 20-carbon arachidonic acid (AA), which can be chan-
neled toward eicosanoid synthesis [1]. The generation of AA
by cPLA2 is a rate-limiting step for biosynthesis of eicosanoids,
which include prostaglandins (PGs), thromboxanes (TXs), and
leukotrienes (LTs). PGs and TXs, which are collectively
referred as prostanoids, are generated by the two isoforms of
cyclooxygenases (COX), COX-1 and COX-2, whereas LTs
are generated by 5-lipoxygenase (5-LOX) [1,2]. Although both
COX enzymes generate PGs, COX-1 is constitutively
expressed in most normal cells at the basal level and is consid-
ered to regulate a number of housekeeping functions such as
vascular hemostasis, renal blood flow, and glomerular function
[1,2]. On the other hand, COX-2, which is inducible in nature,
is mostly expressed at sites of inflammation and cancer [1,2].
Expression of COX-2 can be triggered by cytokines, growth
factors, and other proinflammatory stimuli [2]. Cell- and/or
tissue-specific gene expression of COX-1 and COX-2 has been
reported in different organs and tumors [3–5]. Moreover,
COX-2 overexpression induces tumors in COX-2 transgenic
mice, whereas the COX-2 inhibitors coxibs induce oxidative
stress and reduce polyps associated with colon cancer [2,6,7].
Fibroblasts have a wide distribution throughout the body.
Owing to their ability to secrete extracellular matrix (e.g., col-
lagen) and release proinflammatory mediators [8], fibroblasts
are involved in various pathophysiological conditions such as
arthritis, cancer, lung fibrosis, wound healing, and stem cell
maturation [8]. Fibroblastic COX-1 and COX-2 activity [8]
can be modulated by various receptors such as PGE receptors
(EP receptors) and Toll-like receptors (TLRs) [1,2,8]. These
receptors may influence eicosanoid synthesis, growth, chemo-
taxis, matrix, and matrix metalloprotease synthesis [1,2]. We
therefore chose to use fibroblasts over macrophages for the
present study, in line with our previous investigations on the
regulation of COX and PGs in peripheral blood leukocytes,
chondrocytes (differentiated fibroblasts), and synovial fibro-
blasts in human arthritis [9–11]. We expect our systems
approach (genomic, metabolomic, protein-interatomic, and
proteomic) from the same cells will allow identification of com-
mon and distinct functions of the two closely related COX iso-
zymes [12,13] in sterile inflammation, innate immune response,
and homeostasis in the cells.
The uncontrolled production or defective expression of
COX-1 or COX-2 has been recognized as a health risk
[14,15]. Similarly, nonsteroidal anti-inflammatory drugs
(NSAIDs) and COX-2 inhibitors (coxibs) also exhibited health
risk in large-scale population studies [16,17]. The Food and
Drug Administration (FDA) of the United States hasrecommended that coxibs be avoided in individuals with an
elevated risk of cardiovascular disease (CVD) and in patients
with established CVD [16,17], since the drugs increased the risk
of ischemic CVD, heart failure, increased blood pressure, and
cardiac arrhythmia [2,16,17]. One explanation of these adverse
events is the differential accumulation of TXs, LTs, and PGs in
the presence of coxibs and/or decreased level of prostacyclins
[2,6–8,9–11] and/or ‘‘non-PG effects” of COX inhibitors
[18–20]. Inhibition of COX-2 by coxibs in human arthritis
not only curbs COX-2-mediated PGs but also shifts prosta-
noid synthesis toward the COX-1-mediated pathway [3,10].
Unlike COX-2, the participation of COX-1 has been sub-
verted, for its involvement in inflammation [1,2]. For example,
the anti-inflammatory effects of a highly-selective coxib were
evident only when administered at doses that are inhibitory
for COX-1, indicating a substantial contribution of COX-1
in inflammation [2].
IL-1b is a proinflammatory factor with a wide spectrum of
metabolic, physiological, homeostatic, inflammatory, sterile
inflammatory, and immune activities in diseases [21–23]. Ster-
ile inflammation is caused by cell damage in trauma, ischemia,
ischemia–reperfusion, etc. via endogenous ligands, such as
high-mobility group protein B1(HMGB1), amyloid, S100 pro-
teins, and heat shock proteins (HSPs) [24,25]. It has been
implicated in complex diseases, with the upregulation of IL-1
and eicosanoids as the common denominator [1,9,21–23].
In the present study, we report the alternation in gene
expression and end products of lipid synthesis for COX-1,
COX-2, and 5-LOX pathways in COX-1-/- (COX-1-ablated)
and COX-2-/- (COX-2-ablated) cells. We demonstrate the
dominant role of COX-1 at the genomic, redox, and meta-
bolomic levels in COX-2-null cells. In addition, gene array
data also agree with the metabolic activity of eicosanoids
and redox changes in COX-2-/- cells.
Results
Gene expression arrays and hierarchical clustering in mouse
fibroblasts
In the present study, we utilized knockout cells to eliminate the
variables previously observed when using COX-1/COX-2 inhi-
bitors to dissect the functional roles of COX-1/COX-2, such as
‘‘non-PG effects”, specificity- and concentration-dependent
outcomes [3,12,13,16–20].
Mouse fibroblast cells were obtained from WT cells (WT),
COX-1-/-, and COX-2-/- mice. In addition, WT cells stimulated
with 10 ng/ml IL-1b served as a positive control to procure an
‘‘IL-1b inflammatory signature” at the genomic level. All the
cells were subjected to gene expression arrays [26–28] and as
shown in Figure 1A. We implemented bioinformatics analysis
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Figure 1 General scheme for experimental conditions, bioinformatics analysis, and hierarchical clustering of genes
Gene expression arrays were performed on wild-type control (WT), WT + IL-1b, COX-1-/-, and COX-2-/- fibroblasts (A). Hierarchical
clustering was performed using median-centered gene expression among WT, COX-1-/-, and COX-2-/- cells (B), as well as WT,
WT+ IL-1b, COX-1-/-, and COX-2-/- cells (C). In the heat map, the color toward green indicates lower expression from median while red
indicates higher expression from the median center. The heat map shows differentially-expressed transcripts (FC 60.5 or P1.75) only.
FC, fold change.
Islam ABMMK et al /Omic Analysis in COX-ablated Cells 83to identify specific transcripts that were upregulated by 1.75-
fold or downregulated by 0.5-fold in COX-1-/-, COX-2-/-,
and IL-1b stimulated WT cells, respectively, when compared
to basal gene expression in WT cells. Hierarchical clustering
of gene transcripts showed altered gene expression in COX-
1-/- and COX-2-/- cells as compared to WT cells (Figure 1B;
Figure S1 for high resolution and gene annotations). These
also include COX-1 and genes involved in eicosanoid synthesis,
inflammation, homeostasis, and cell cycle in COX-2-/- cells.
As a result, we found expression of 223 transcripts was up-
or downregulated in IL-1b-induced WT cells (WT + IL-1b),
representing the ‘‘IL-1b inflammatory signature” (Figure 1C,
Figure S2, and Table S1). About 50% of these 223 transcripts
were also modulated as the IL-1b inflammatory signature in
COX-1 or COX-2 ablated cells (Figure 1C, S2 and
Table S1). Expression of some highly or lowly modulated tran-
scripts by IL-1b [21–25], such as acute phase protein serum
amyloid A3 (SAA3) and IL33 was further plotted (Figure S3).
As expected, IL-1b induced the expression of COX-2 but not
COX-1, comparing WT vs. WT+ IL-1b cells [21–25].Gene expression arrays of eicosanoid metabolismTo understand the role of COX-1, we focused on the alter-
ations in gene expression in COX-2-/- cells. Sixty-five tran-
scripts were identified to be involved in eicosanoid, lipid, and
redox metabolism pathways. These transcripts were grouped
into different eicosanoid pathways as shown in the heat map
of differentially-expressed transcripts from WT, WT+ IL-
1b, COX-1-/-, and COX-2-/- cells (Figure 2). More than 25%
of these 65 transcripts that were upregulated in IL-1b stimu-
lated WT cells were also spontaneously augmented in
COX-2-/- cells.
The genes of PLA2-group [29], including Pla2g4, Pla2g6,
and Pla2g7, were highly expressed in COX-2
-/- followed
by COX-1-/-, IL-1b+WT, and WT cells (Figure 2 and
Table S2). Compared to WT and COX-1-/- cells, increased
expression of genes encoding PGE synthase (Ptges) and
PGI2 (as called prostacyclin) synthase (Ptgis) was detected
in COX-2-/- cells. Glutathione S-transferases (GSTs) are
Figure 2 Gene expression of eicosanoid metabolism in COX-1-/-, COX-2-/-, WT, and WT+ IL-1b cells
The differentially-expressed transcripts were clustered into different pathways. Gene expression is represented as fold change in relation to
WT cells from low to high in color gradient (from green to red). Red indicates a higher expression, while green indicates a lower
expression. The average baseline fold change of all the three housekeeping transcripts was 1.0 ± 0.3.
84 Genomics Proteomics Bioinformatics 14 (2016) 81–93key enzymes in the synthesis of various LTs [30,31]. There
was an increase in genes encoding various GST isoforms,
including GST theta 1 (Gstt1), GST alpha 4 (Gsta4), GST
kappa 1 (Gstk1), and microsomal GST 1 and 2 (Mgst1,Mgst2), in COX-2-/- cells as compared to WT, WT+ IL-
1b, and COX-1-/- cells. Similarly, increased expression was
also revealed for genes encoding superoxide dismutase
(Sod), peroxiredoxin (Prdx), and proteins involved in the
Islam ABMMK et al /Omic Analysis in COX-ablated Cells 85phospholipid translocation, such as scramblase 2 (Plscr2)
[30–33].
Network analysis
The Database Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING) contains information on about
5.2 million proteins in 1133 species from experimental data,
computational prediction methods, and public text collections.
Data are weighted and integrated with a confidence score cal-
culated for all protein interactions. STRING allows merging
of gene expression arrays and metabolic activity at the level
of protein–protein interactome [13,34]. Using the edge infor-
mation present in the STRING database, protein–protein
interaction map (Figure 3) was derived from the gene expres-
sion data in this study. In WT cells, there exist interactions
of different proteins in the eicosanoid pathways (Figure 3A),
representing the background signal of WT cells. The map
shows the interactions among the functional genes/proteins
associated with 5-, 12-, and 15-LOXs, COX-1 and COX-2,
and lipid metabolism. Figure 3 showed an increase in gene/
protein activities in the following order of magnitude: COX-
2-/- > COX-1-/- = IL-1b+WT>WT cells. The differences
in redox-related protein were more pronounced in COX-2-/-
cells (Figure 3D). For example, expression of NAD(P)H dehy-
drogenase quinone 1 (NQO1) and its receptor aryl hydrocar-
bon receptor (AhR) was increased in COX-2-/- as compared
to WT, COX-1-/-, and IL-1b-stimulated cells. NQO1 is induced
during cellular stress, detoxification, tumors, tardive dyskine-
sia, and hematotoxicity [35,36]. AhR has been shown to regu-
late xenobiotic-metabolizing enzymes such as cytochrome
P450, which is involved in eicosanoid metabolism [36]. Taken
together, these interaction maps showed that unlike WT and
COX-1-/- cells, COX-2-/- cells exhibited a distinct protein–
protein interaction signature.
Lipidomic studies and strategy
Accumulation of PGE2 and PLA2 in COX-1
-/- and COX-2-/-
cells
We integrated the omics analysis as shown in Figure S4 [37].
We next selected stable end-metabolites (from WT and COX
mutants), which can be quantitatively assayed and may also
represent pathways involved in eicosanoid synthesis. The
expression levels of genes encoding isoforms of PLA2 of the
groups VII (Pla2g7), IVA (Pla2g4), and VI (Pla2g6)
were spontaneously upregulated in the following order:
COX-2-/- > COX-1-/- = IL-1b+WT cells (Figure 2 and
Table S2). Basal levels cPLA2 were not detected by western
blot analysis in unstimulated fibroblasts in this and other stud-
ies [3,29]. Nevertheless, COX-1-/- and COX-2-/- cells (and WT
+ IL-1b cells [3,38]) showed upregulation of cPLA2 as deter-
mined by Western blot analysis (Figure 4). These data not only
confirmed previous observations [29] with respect to the func-
tional role of cPLA2, but also identified new classes of PLA2:
the lipoprotein-associated phospholipase A2 (Lp-PLA2)
encoded by Pla2g7, which is associated with eicosanoid
metabolism in these mutant fibroblasts.
Consistent with the upregulated expression of cPLA2 in
COX-ablated cells, the levels of PGE2 were significantly
increased (3–4-folds) in COX-1-/- and COX-2-/- cells, althoughit is present at a basal level in WT cells (Figure 4A). Similar
observations were made after normalizing the amount of
PGE2 with the cellular DNA content (Figure 4B). We obtained
the similar results as those reported by Ballou et al. [3]. The
increased levels of PGE2 was accompanied by increases in
the expression of Ptgs1, Ptgs2, Acsl4, Elovl6, Fads1, Plscr1,
Plscr2, Ptgis, and Ptges, which are involved in lipid metabo-
lism (Figure 2 and Table S2). These results suggest an increase
in the synthesis and compensation of the dominant PG (e.g.,
PGE2) with other enzymes in lipid metabolism by COX-1
and COX-2 pathways in the absence of either COX isoforms.Regulation of PGE2 in COX-1- and COX-2-ablated cells
We then examined if the expression of COX-1 and COX-2 was
sensitive to inhibitors (indomethacin) and activators (IL-1b
and/or AA) of COX-1 and COX-2 in WT, COX-1-/-, and
COX-2-/- cells (Table 1). We found that indomethacin signifi-
cantly inhibited PGE2 accumulation in COX-1 or COX-2-
ablated cells, confirming that both enzymes were indepen-
dently involved in the generation of PGE2 [1,2]. On the other
hand, we also tested the effects of the endogenous activator
AA (Figure 5) and found that AA significantly increased the
levels of PGE2 in WT and COX-1
-/- cells, but not in
COX-2-/- cells. These experiments show the importance of
endogenous AA as a rate limiting step for regulation of
COX-1 and COX-2 pathways [1–3,39].Analysis of prostanoids in COX-1-/- and COX-2-/- cells
PGE2 is one of the dominant prostanoids in COX-ablated
fibroblasts as observed in other cell types [1,2]. We examined
the production of PGD2, TXB2, 6-keto-PGF1a, and PGF2a,
which has not been examined previously in these COX
mutants (Figure 6). The amount of PGD2 was significantly
increased in the COX-1-/- and COX-2-/- cells as compared
to that in WT cells. Compared to WT cells (around 170–
180 pg/ml), the amount of TXB2, a stable and an inactive
metabolite of TXA2, was significantly increased in COX-2
-/-
but not COX-1-/- cells. Different from PGD2 and TXB2,
PGF1a was identified in low concentrations in WT cells,
but increased significantly in both COX-1-/- and COX-2-/-
cells. On the other hand, PGF2a levels were relatively high
in WT cells but significantly increased in COX-2-/- cells,
while only marginal increase was detected in COX-1-/- cells.
In addition, there was a 1–5-fold increase in several prosta-
noids (like PGE2) in the presence of exogenous AA (data
not shown). In summary, as compared to WT cells, the levels
of TXB2 and PGF2a were significantly higher in COX-2
-/-
cells but not COX-1-/- cells. There was a compensation of
basal levels of PGE2, PGD2, and PGF1a in COX-1
-/- and
COX-2-/- cells due to increased activity of cPLA2 and high
levels of common substrate: AA in both mutants. This leads
to an imbalance in the basal levels of prostanoids in the
mutants (by the COX-1 and COX-2 pathways) as compared
to WT cells.
Cross-talk between COX and 5-LOX pathways in COX-2-/- cells
The shift from PGE2 to LTB4 in cytokine-activated cells in the
presence of coxibs has been reported in human arthritis-
affected tissues and cells [9,40]. In the present study, we com-
pared the contributions of COX-1 and COX-2 in the 5-LOX
Figure 3 Protein–protein interactions in eicosanoid metabolism
Protein–protein interactome map of the selected group of eicosanoid metabolism genes are presented in a network model in WT (A),
WT + IL-1b (B), COX-1-/- (C), and COX-2-/- (D) cells. Genes/proteins are represented as nodes and interactions are represented as edges.
Gene expression is represented as fold change in relation to WT cells from low to high in color gradient (from green to red; fold
change = 0–2.5). Fold change is set as 1 for WT. The highest intensity red color in this scale indicates that fold changeP2.5-fold that of
basal levels.
86 Genomics Proteomics Bioinformatics 14 (2016) 81–93pathways with and without any stimulation (Figure 7). COX-
2-/- and COX-1-/- cells showed a spontaneous release of
LTB4, although it was much higher in COX-2
-/- cells. In addi-
tion, extra AA or IL-1b significantly increased the levels of
LTB4 accumulation in COX-1
-/- cells, which is not the case
for COX-2-/- cells. In summary, we demonstrated the differen-
tial and preferential contribution of LTB4 synthesis by the
COX-1 pathway over the COX-2 pathway.
Discussion
The present study describes the common and dissimilar func-
tional interactions of the COX isozymes at the cellular level.
Previous pharmacogenomics analysis showed inhibition of
PGE2 by coxib in human arthritis-affected blood cells and
cartilage, resulted in altered gene expression [9–11]. Coxibs
or statins with different chemical structures and similar
pharmacological targets, elicited distinct side effects, changesin protein profile and gene expression [1,2,16–19,41–43]. It
should be noted that altered gene expression incited by coxibs
may not necessarily account for the inhibition of COXs and
PGs, since some effects of coxib treatment cannot be reversed
by the addition of exogenous prostanoids [18–20,42,43]. Fur-
thermore, the differential physiological actions of coxibs for
curbing pain and inhibiting colon cancer are concentration
dependent [1,2].
Role of COX-1 and COX-2 in inflammation and inflammation
resolution
IL-1b and other members of the growing superfamily of IL-1
are involved in sterile inflammation under various pathophys-
iological conditions [21–25]. Approximately 50% of transcripts
modulated in COX-1- or COX-2-ablated cells were also
observed in the ‘‘IL-1b inflammatory signature”. Since inflam-
masome and COX-2 pathways are induced by IL-1b, the
04
8
12
16
* 
* 
WT COX-1-/- COX-2-/- 
Western blot 
Am
ou
nt
 o
f P
G
E 2
 (n
g/
m
l) 
0
0.4
0.8
1.6
COX-1-/- COX-2-/- 
Am
ou
nt
 o
f P
G
E 2
 (n
g/
µg
 D
N
A 
) 
A B 
0.2
0.6
1.2
1.0
1.4
WT
* * 
cPLA2 
Figure 4 Spontaneous production of PGE2
The spontaneous release of PGE2 in cell supernatant was examined by radioimmunoassay (RIA). The amount of PGE2 in COX-1
-/- or
COX-2-/- was presented in relation to WT cells (A) and after normalized with cellular DNA (B). The protein levels of cPLA2 in different
cell samples were detected using Western blotting. Data are expressed as mean ± SEM (n= 3 for each experiment). Student’s t-test was
performed for statistical analysis and significant differences are labeled with *(P< 0.01) when compared to WT cells.
Table 1 Effect of indomethacin on PGE2 production in COX-1- and COX-2-ablated cells
Condition PGE2 at 24 h (ng/ml) PGE2 at 48 h (ng/ml)
COX-1 -/- cells
Control (basal COX-2 activity) 6.8 ± 1.3 5.3 ± 2.6
Indomethacin treatment 2.5 ± 0.2* 2.2 ± 1.0*
COX-2 -/- cells
Control (basal COX-1 activity) 8.9 ± 1.8 15.3 ± 2.8
Indomethacin treatment 5.3 ± 1.1* 2.7 ± 0.6*
Note: * indicates significant difference in the amount of PGE2 (mean ± SEM) spontaneously released by cells treated with indomethacin (5 lg/ml)
in relation to the respective untreated control cells as determined by Student’s t-test, n= 3 (P< 0.05).
Islam ABMMK et al /Omic Analysis in COX-ablated Cells 87intricate roles of COX-2 during sterile inflammation and
innate immunity were not surprising [23,24]. However, the
inflammatory response exhibited by the upregulated COX-1
expression (in the absence of COX-2 activity) was certainly
perplexing. These results further support the previously over-
looked role of COX-1 within and beyond eicosanoid metabo-
lism and inflammation. Others and we have shown that low
levels of PGE2 exhibit proinflammatory activity by activating
NFjB pathway [44]. However, prolonged activation of COX
by IL-1b and high levels of PGE2 foster inflammation resolu-
tion by inhibiting the NFjB pathway [45,46]. Prolonged and a
constitutive upregulation of PGE2 (in COX-ablated cells and
IL-1b-stimulated WT) triggered the upregulation (by 2–3-
fold) of a gene (Nfkbiz), which inhibits NFjB functions [44].
COX-1 or COX-2 in collaboration with other mediators
may participate in inflammation, inflammation resolution,
and cancer [1,2,45,46]. The multifunctional transcription fac-
tor AhR regulates many genes including COX-2, but not
COX-1 [36,47–52]. AhR-/- mice have been reported to develop
heightened inflammatory responses with decreased induction
of COX-2, lipid peroxidation, and oxidative stress [52]. AhRagonist leflunomide, which is used for the treatment of
rheumatoid arthritis (RA), exhibits anti-inflammatory activity
[51]. However, another agonist of AhR, TCDD, induces COX-
2 (but not COX-1) transcription in cancer due to the presence
of the AhR binding site (xenobiotic response elements, XRE)
in the COX-2 promoter region [36,47]. The upregulation of
AhR was only observed in COX-2-/- but not in COX-1-/- cells.
The COX-2-/- cells (with amplified COX-1 activity) also exhib-
ited increased oxidative stress with elevated levels of NQO1,
GSTs, PRDX2, and SODs. The distended levels of AhR in
COX-2-/- cells may participate in not only detoxification
[35,36], but also anti-inflammatory activity [51]. These prelim-
inary observations require further experimental studies to bet-
ter understand the functional relationships between AhR and
COX-1.
Role of PLA2 isoforms and COX-1 in inflammation
In the current studies, the differential expression of various
PLA2 isoforms in COX-1
-/- and COX-2-/- cells were induced
by the exclusive COX-2 or COX-1 pathways, respectively.
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Figure 6 Differential synthesis of prostanoids in WT, COX-1-/-,
and COX-2-/- cells
Amount of PGD2, TXB2, PGF1a, and PGF2a in cell supernatant
was examined by ELISA at 24 h of incubation. Data are expressed
as mean ± SEM (n= 3 for each experiment). Significance levels
were calculated using Student’s t-test. Significant differences in the
amount of prostanoids between COX-ablated and WT cells are
indicated with * for COX-2-/- cells and # for COX-1-/- cells,
respectively (P< 0.05).
Figure 7 Effect of AA and IL-1b on the level of LTB4 in COX-1
-/-
and COX-2-/- cells
The amount of spontaneous release of LTB4 in the COX-1
-/- and
COX-2-/- cells in the presence or absence of AA (A) or IL-1b (B)
was evaluated by ELISA. Significant alteration in the amount of
LTB4 (P < 0.05) between COX-1
-/- and COX-2-/- cells is indicated
with #, while difference between the treated and untreated samples
in the same cell groups is indicated with *. All data are expressed
as mean ± SEM (n= 3). Significance levels were calculated using
Student’s t-test.
88 Genomics Proteomics Bioinformatics 14 (2016) 81–93The current literature strongly implicates PLA2G4 as the pri-
mary enzyme in polyunsaturated fatty acid release for eicosa-
noid biosynthesis [12,29]. Pla2g4-/- mice were not able to
produce eicosanoids [29,37]. The upregulated Pla2g4 in IL-
1b-induced WT, COX-1-/-, and COX-2-/- cells accounted for
the increased eicosanoid synthesis [3,29,37]. Transfection of
Pla2g6 results in upregulation of PGE2 and PGF2a [29,37].
Indeed, unlike in COX-1-/- cells, an increase in Pla2g6 wasassociated with increased levels of PGF2a. in COX-2
-/- cells
in the present study. Lp-PLA2 (Pla2g7) was upregulated in
COX-2-/- cells and plaque forming inflammatory cells in
atherosclerosis [29,37]. The differential expression of isoforms
of PLA2 supports the distinct role of COX-1 in mounting an
inflammatory response in the absence of COX-2.
Our studies suggest that COX-1 upregulates gene expres-
sion and metabolic activity, which results in a significant
increase in the synthesis of prostanoids and redox-related
activity in COX-2-/- cells. It should be noted that COX-2-/-
fibroblasts showed a nearly fourfold increase in COX-1 gene
expression as compared to WT cells. Although COX-1 is
regarded as a ‘‘constitutive enzyme” [1–3], COX-1 gene expres-
sion is upregulated in the colon and ovarian cancers [53,54].
Estradiol also stimulates gene expression of PLA2 and COX-
1 in endothelial cells [55]. Von Moltke et al. studied the role
of COX-1 during systematic inflammation induced by flagellin
in mice [56]. They showed that COX-1-derived products drive
the initial phase of the inflammatory process, whereas COX-2
upregulation followed a few hours later [56]. These observa-
tions highlight the new role of COX-1-generated eicosanoids
and physiological consequences in vivo and also support the
hypothesis that the basal activity of COX-1, when placed in
a pivotal position, can mount an inflammatory response with
an ‘‘eicosanoid storm” to compensate for the multifunctional
eicosanoids, lipids, and redox-related mediators.Regulation of metabolites by COX-1, COX-2, and LOX
COX-1 and COX-2 differ in metabolic functions. Unlike
COX-1, COX-2 can metabolize dihomo-c-linolenic and
Islam ABMMK et al /Omic Analysis in COX-ablated Cells 89eicosapentaenoic acid in addition to AA [37]. Another note-
worthy difference between COX-1-/- and COX-2-/- fibroblasts
is their ability to synthesize different quantities and forms of
PGs, TXs, LTs, and lipids. Changes in levels of eicosanoids
may regulate each other. For example, an increased produc-
tion of PGD2 in human arthritis-affected tissues increases the
accumulation of PGE2, PGF1a, PGF2a, and TXB2 but inhibits
LTB4 [57]. The expression of COX-1 can have far-reaching
effects on lipid metabolism. For example, Ma et al. reported
significant changes in the levels of phosphatidylserine, triacyl-
glycerol, and cholesterol, which alter the cholesterol-to-
phospholipid ratio in COX-2-/- mice and may impart resistance
to neuroinflammation [58]. Thus increasing the activity of
COX-1 (in COX-2-/- cells) not only regulates eicosanoid
synthesis but also augments lipid metabolism as described in
Figure 2. An increased activity of COX-1 increased the levels
of LTB4 in COX-2
-/- cells that were comparable to those
induced by IL-1b- or AA-induced COX-1-/- cells. Similar
effects were observed in human osteoarthritis-affected carti-
lage that spontaneously released PGE2 and LTB4 in ex vivo
models [9]. The proinflammatory activity of LTB4 is well doc-
umented in fibroblasts. Expression of TNFa and IL-1b isPLA2 
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Figure 8 Differential regulation of COX-1 and COX-2- in fibroblasts
As compared to the basal levels of WT (A), COX-2-/- cells (B) showed
leading to upregulated PGs and LTs and compensation of the COX-2 p
LTB4 without any stimulation. COX-2-/- cells also exhibited an
inflammatory and proinflammatory activities with an increased redox
compensation of PGE2 but not TXB2 and PGF2a. cells. LTB4 increased
only step up to some of the functions of COX-2, but also exhibit regula
radicals, pro- and anti-inflammatory activity. Different symbol sizes re
Tables S1 and S2.increased by LTB4 but inhibited by LTB4 inhibitors, such as
MK886 and bestatin [1,2].
Increase in redox molecules in COX-ablated cells
The increase in GSTs in COX-2-/- cells was higher than that in
COX-1-/- cells, followed by that inWT cells. GSTs contribute to
the detoxification of xenobiotics and endogenous peroxided
lipids, and biosynthesis of LTs [30–32]. Peroxiredoxins function
as antioxidant enzymes that also control inflammation-induced
peroxide levels by removing H2O2 [59]. Mice lacking peroxire-
doxin develop severe hemolytic anemia and hematopoietic can-
cers, and have shortened lifespan [59]. Microsomal PGE
synthase-1 (mPGES-1) requires glutathione as a co-factor
[37]. One of the most notable observations is the increase in
gene expression of NQO1 and AHR. AhR-mediated NQO1
gene expression is increased by a variety of antioxidants, tumor
promoters, and H2O2 [35,36]. COX-2
-/- cells showed an increase
in the pentose phosphate pathway (HMP shunt, Amin AR
unpublished data). The HMP shunt is a metabolic redox sensor
and modulates gene expression during an anti-oxidant response
[60]. These types of cellular events that lead to oxidative stressPGF1αTXB2 PGD2 
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an increased expression of COX-1 and various isoforms of PLA2,
athway. COX-1-pathway preferentially channeled AA to PGs and
increased gene expression associated with detoxification, anti-
activity. The basal level of COX-2 in COX-1-/- cells (C) showed
only in the presence of AA or IL-1b. In summary, COX-1 can not
tion of different eicosanoids, redox reactions detoxification of free
present gene and/or protein expression. Abbreviations are listed in
90 Genomics Proteomics Bioinformatics 14 (2016) 81–93and ‘‘Warburg effect” [60] are interlinked with the regulation of
COXs, NFjB activation during inflammation induces intracel-
lular ROS [46,47,60]. COX-1 peroxidase activity has been
reported to serve as an intracellular signal leading to NFjB
activation [47,60]. The possibility that the products of COX-1
and COX-2 may also be sensors and/or inducers for such
imbalanced redox activity is compelling.
The current understanding of COX-1 in inflammation and
homeostasis is constantly evolving. These studies advocate that
COX-1 may participate in regulating sterile inflammation,
which is more latent and subtle. There are significant collabora-
tions and functional redundancies between COX-1 and COX-2.
For example, the essential and collaborative role of both
COX-1 and COX-2 has been observed in ear inflammation
and arthritis models of mice [1,61]. In addition, in the K/BxN
serum–transfer model of arthritis, COX-1-derived PGs, in
particular PG12, contributed remarkably to initiating and
prolonging the pathology [1]. Similarly, both COX isoforms
contributed to PG production in the carrageenan model of
inflammation, depending on the type of stimulus and tissue-
specific expression of COXs [1]. The coordination and collabo-
ration of the COXs remain well balanced, especially in vivo, in
an inflammatory process, but may depend upon the availability
of the COX isoform, time course, and intensity of the inflamma-
tion. It is apparent that if either COX isoform is functionally
unavailable, the other becomes pivotal and attempts to com-
pensate the events with a different intensity and/or tissue speci-
ficity [9], as observed in COX-1 and COX-2 knockout mice and
fibroblasts [3–10,14,15,39]. Figure 8 summarizes the changes
observed in WT, COX-2-/-, COX-1-/- cells based on genomics
and metabolomics studies described in this study These investi-
gations paint a broader picture of eicosanoid synthesis and
signaling, gene expression, and lipid metabolomics, which can
identify and connect unforeseen functions of COX-1 and COX-2.
Conclusion
This study describes the functional role of COX-1 and COX-2
at the cellular, metabolic, and genomic levels. Dysregulation of
COX-1 or COX-2 results in a burst of gene expression within
and beyond eicosanoid and redox metabolism in fibroblasts.
The changes in basal gene expression of upregulated COX-1
in COX-2-/- cells exhibited a mixture of pro- and anti-
inflammatory response, as well as an activated redox signature
at the genomic level. The basal levels of COX-1 > COX-2 are
involved in channeling LTs from COX to 5-LOX pathway.
There is compensation of eicosanoids and redox metabolism
by COX-1 and COX-2 and vice versa. This systems approach
allows the integration of genomic, bioinformatic, and lipidomic
datasets. It opens new areas of biomarkers and COX regulation
beyond eicosanoid metabolism, which would help to develop
safer next generation of coxibs by taking into consideration
the board impact of COX genes on other metabolic pathways.
Materials and methods
Reagents
Cell culture media and fetal calf serum (FCS) were obtained
from Gibco BRL (Invitrogen, Carlsbad, CA). ELISA kits forthe detection of PGs (PGD2, PGF1a, and PGF2a), TXs
(TXA2), and LTs (LTB4) and AA were purchased from
Chemicon International (Temecula, CA). ELISA was used to
measure the levels of prostanoids and LTB4 [8,9]. PGE2 was
estimated by radioimmunoassay (RIA) as previously reported
[9,62,63]. IL-1b was purchased from Pepto Tech (Princeton,
NJ).
Isolation and culture of COX-deficient mouse cells
Lung fibroblast cells were collected from WT C57BL/6J (B6),
as well as COX-1 and COX-2 deficient mice [3–5]. The COX-
1-/- and COX-2-/- cell lines were immortalized and cultivated
from fibroblasts as previously reported [3–5,62]. Briefly lung
tissues were dissected into small pieces and grown in MEM
medium [3–5,62], with 10% FCS in a humidified incubator
with 5% CO2. After 3 weeks of culture, only fibroblasts contin-
ued to grow. The cells were maintained in DMEM containing
high glucose and supplemented with Pen/Strep (100,000 U/l
penicillin G and 100 mg/l streptomycin sulfate), nonessential
amino acids (0.1 mM), fungizone (1 mg/l amphotericin B), glu-
tamine (292 mg/l), ascorbic acid (50 mg/l), and 10% FCS. The
cells were incubated with 0.5 lM of AA or 10 ng/ml of IL-1b
as endogenous or receptor mediator inducer of eicosanoids.
Labeling and hybridization of microarray gene chips
Total RNA was isolated and labeled with the ENZO BioArray
High-yield RNA transcript labeling kit (Affymetrix, Santa
Clara, CA) and then hybridized using U74Av2 Murine
Genome Array (Affymetrix) as described [26]. Genes repre-
senting 12,492 transcripts from the A chip and those annotated
till 2012 were identified as present calls as per the manufactur-
ers’ recommendations.
Normalization of the microarray data and bioinformatics
analysis
The Affymetrix microarray image files for each sample were
imported into the Affymetrix Expression Console Software
package (www.affymetrix.com) to calculate the robust multi-
array analysis-normalized gene expression signals for 12,488
mouse gene probe sets on the U74Av2 arrays. The binary log-
arithm signal values were then exported into a MS Excel
spreadsheet for data analysis. The log transformed expression
values ranged from 6.2 to 15.4. Since the median standard
deviation of the logged signal values across all probe sets for
the replicate samples was small (<0.03), the fold change
(FC) of the gene expression was computed by simply averaging
the logged signal values for the replicate samples for compar-
ison with the logged expression values for a single WT control
sample. Our functional genomics analysis focused primarily on
genes with FC P1.75-fold (upregulation) and 60.5-fold
(downregulation), in relation to WT [26–28]. The normaliza-
tion was verified using four housekeeping genes encoding
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and b
actin, as well as ribosomal proteins L30 (RPL30) and S13
(RPS13), which showed similar expression in all samples [64].
The heatmaps were constructed using Gitools [65] with gene
expression in the WT taken as the baseline for each transcript.
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The hierarchical clustering of median expression value for
every gene was calculated and subtracted from the absolute
expression of each gene in each aforementioned experimental
condition (median centering of genes). Using the tool ‘‘Gene-
sis” and the median-centered gene expression matrix, the hier-
archical cluster of genes (Pearson’s correlation distance and
average linkage) was determined and the annotated data were
presented as heatmaps.
Interaction network
Interactions among proteins encoded by the selected group of
eicosanoid metabolism genes were presented in a network
model. Edge information among the nodes was extracted using
the online tool STRING (v9.1) [66] and the interaction net-
work was visualized using Cytoscape (v 3.1) [67].
Eicosanoids detection in WT, COX-1-/-, and COX-2-/- cell
supernatants
Supernatants of WT, COX-1-/- and COX-2-/- cells were ana-
lyzed using ELISA or RIA [8,9] to quantitate eicosanoids.
The cells were seeded in triplicates unless otherwise specified
and cultured for 24 h.
Effects of AA on eicosanoid synthesis in COX-ablated cells
Cells were seeded in triplicate at a concentration of
10,000 cells/cm2 in 6- or 24-well plates. After treatment with
0.5 lM AA for 15 min, the cells were washed and replenished
with fresh medium. The levels of eicosanoids were monitored
since then and the experiments were terminated between 18
and 24 h before the fibroblasts start the exponential growth.
Release of eicosanoids into the medium was subsequently esti-
mated using ELISA or RIA as previously reported [8,9,63].
Western blot analysis
The WT, COX-1-/-, and COX-2-/- cells were cultured for 18 h,
and cell extracts were prepared using a total protein extraction
reagent (Pierce, Rockford, IL) as per manufacturer’s instruc-
tions and other studies [3,62,63]. Total protein (30 lg per sam-
ple) was separated by 10% SDS–PAGE and transferred onto a
nitrocellulose membrane (Schleicher & Schuell, Keene, NH).
After blocking with 3% BSA for 2 h, the blots were incubated
with rabbit anti-cytosolic-PLA2 antibody (1:500, Santa Cruz
Biotechnology, Santa Cruz, CA). Bound antibody was
detected by anti-rabbit IgG-conjugated horseradish peroxidase
(1:5000, Santa Cruz Biotechnology, Santa Cruz, CA) and
developed using the enhanced chemiluminescence ECL plus
(Amersham, Arlington Heights, IL).
Statistical analysis
The statistical analyses were performed using GraphPad Soft-
ware (v1.14) (San Diego, CA). Student’s t-test was used to ana-
lyze the data unless otherwise specified. Data from each
experiment are represented as mean ± standard deviation.Differences between the mean values of the control and exper-
imental groups are considered significant with P < 0.05.
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